CGH
GMAB icon

Crossmark Global Holdings’s Genmab GMAB Stock Holding History

Crossmark Global Holdings’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$317K Sell
11,531
-3,983
-26% -$106K ﹤0.01% 1040
2026
Q1 		$416K Sell
15,514
-7,965
-34% -$239K 0.01% 895
2025
Q4 		$723K Sell
23,479
-18,334
-44% -$571K 0.01% 712
2025
Q3 		$1.28M Hold
41,813
– – 0.02% 560
2025
Q2 		$864K Sell
41,813
-3,034
-7% -$62.3K 0.01% 667
2025
Q1 		$878K Buy
44,847
+3,225
+8% +$67.6K 0.02% 655
2024
Q4 		$868K Buy
41,622
+3,377
+9% +$74.2K 0.02% 621
2024
Q3 		$932K Sell
38,245
-32,387
-46% -$866K 0.02% 634
2024
Q2 		$1.77M Buy
70,632
+7,242
+11% +$205K 0.03% 431
2024
Q1 		$1.9M Sell
63,390
-4,285
-6% -$126K 0.04% 440
2023
Q4 		$2.15M Sell
67,675
-6,138
-8% -$193K 0.04% 379
2023
Q3 		$2.62M Buy
73,813
+135
+0.2% +$5.14K 0.06% 325
2023
Q2 		$3.11M Buy
73,678
+6,574
+10% +$262K 0.07% 313
2023
Q1 		$2.53M Buy
67,104
+6,545
+11% +$252K 0.06% 342
2022
Q4 		$2.57M Sell
60,559
-2,924
-5% -$120K 0.06% 328
2022
Q3 		$2.04M Buy
63,483
+1,813
+3% +$63.7K 0.06% 352
2022
Q2 		$2M Buy
61,670
+1,270
+2% +$41.1K 0.05% 380
2022
Q1 		$2.19M Buy
60,400
+1,910
+3% +$65.5K 0.05% 388
2021
Q4 		$2.31M Buy
58,490
+4,200
+8% +$175K 0.05% 368
2021
Q3 		$2.37M Buy
54,290
+2,610
+5% +$117K 0.06% 342
2021
Q2 		$2.11M Sell
51,680
-5,060
-9% -$195K 0.05% 361
2021
Q1 		$1.86M Sell
56,740
-1,805
-3% -$67.9K 0.05% 396
2020
Q4 		$2.38M Sell
58,545
-90
-0.2% -$3.36K 0.06% 334
2020
Q3 		$2.15M Sell
58,635
-240
-0.4% -$8.68K 0.06% 327
2020
Q2 		$2M Buy
58,875
+5,715
+11% +$156K 0.06% 337
2020
Q1 		$1.13M Buy
53,160
+8,960
+20% +$200K 0.04% 433
2019
Q4 		$987K Buy
+44,200
New +$965K 0.03% 561

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Crossmark Global Holdings's GMAB Position: Q2 2026 in Review

Crossmark Global Holdings reduced its Genmab (GMAB) stake by 26% in Q2 2026, selling an estimated $106K and leaving 11,531 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #1040.

Crossmark Global Holdings first reported a position in GMAB in Q4 2019 and has held it in 27 quarters since. The position peaked at $3.11M in Q2 2023. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Crossmark Global Holdings held 11,531 shares of Genmab worth $317K as of Q2 2026.
  • Crossmark Global Holdings sold 3,983 Genmab shares in Q2 2026, an estimated $106K.
  • Genmab made up ﹤0.01% of Crossmark Global Holdings's portfolio in Q2 2026, its #1040 holding.
  • Crossmark Global Holdings first reported a position in Genmab in Q4 2019 and has held it in 27 quarters since.
  • Crossmark Global Holdings's Genmab position peaked at $3.11M in Q2 2023.
  • 290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.